Good morning everyone, hope you’re savoring the fresh start that comes with the beginning of the week. This is Rachel Cohrs sitting in today. Our morning cup of stimulation comes in the form of a steaming mug of English breakfast tea, as your author isn’t much of a coffee drinker — hopefully Ed will forgive the departure from canon. Here are a few items to help you catch up this Monday, and as always, stay in touch. …
Pfizer (PFE) will buy cancer-drug developer Trillium Therapeutics (TRIL) in a deal that values the company at $2.26 billion, Reuters reports. Trillium develops drugs that boost patients’ immune systems to fight off cancer cells, and its two leading candidates focus on blood cancers.
New data from Israel found that a third dose of the Pfizer-BioNTech (BNTX) vaccine provides four times more protection against Covid-19 infection in seniors than two doses, Forbes tells us. A third dose also performs better in helping avoid hospitalization or serious illness. The United States has plans to begin rolling out booster shots for everyone in September.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
